NCT07759128

A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-07-28Est. Completion: 2028-12-06

Enrollment target: 576 participants

Locations

Del Sol Research Management, Tucson, Arizona, United States
Pharmacology Research Institute, Encino, California, United States
California Neuroscience Research Medical Group, Inc, Sherman Oaks, California, United States
Emerson Clinical Research Institute - Washington, DC, Washington D.C., District of Columbia, United States
Sarkis Clinical Trials - Gainesville, Gainesville, Florida, United States
Clinical Neuroscience Solutions, LLC, Jacksonville, Florida, United States
Accel Research Sites - Maitland, Maitland, Florida, United States
AMR Conventions Research, Inc, Warrenville, Illinois, United States
Research Works, Inc, New Orleans, Louisiana, United States
Adams Clinical Boston, Boston, Massachusetts, United States
Vector Clinical Trials - Las Vegas, Las Vegas, Nevada, United States
Adams Clinical Harlem, New York, New York, United States
Manhattan Behavioral Medicine PLLC, New York, New York, United States
Insight Clinical Trials, Independence, Ohio, United States
Sooner Clinical Research, Inc., Oklahoma City, Oklahoma, United States

Generalized Anxiety Disorder

This study aims to evaluate the clinical efficacy and safety of electroacupuncture (EA) as an adjunctive treatment for g…

Hangzhou, ChinaEst. completion Oct 31, 2027

Intrahepatic Cholangiocarcinoma (Icc)

This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety o…

Guangzhou, ChinaEst. completion Jan 2030

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.